The medical device sector has seen notable shifts by mid-2026. Procurement policies have moved away from a "price-only" approach toward balancing cost and quality, with new anti-involution regulations delivering tangible benefits for innovative devices—including separate bidding groups, pricing premiums, priority inclusion in medical insurance catalogs, and favorable renewal terms. Meanwhile, Chinese medical devices have evolved from mere participants to influential players on the global stage. Full-year 2025 pharmaceutical and device exports reached $111.34 billion with a trade surplus of $20.96 billion, while Q1 2026 exports rose 7.58% year-on-year to $14.81 billion, reversing the decline seen in the previous quarter and signaling a clear recovery.
Hong Kong-listed Medicalc Medical is riding both the "global expansion" and "innovation" waves. On the expansion front, the company embedded itself into overseas distribution networks through strategic acquisitions, with R&D and production centers spanning multiple countries. On the product front, it holds several high-value innovations: China's first multi-channel infusion workstation MP-80, the country's first MRI-compatible infusion workstation HP-80, and the world's first fully automated thromboelastography analyzer Haema TX. With strong technology, proven products, and mature sales channels at home and abroad, Medicalc has already turned profitable and entered a positive earnings phase.
From 2023 to 2025, Medicalc's total revenue reached RMB 1.313 billion, RMB 1.399 billion, and RMB 1.619 billion respectively, reflecting a compound annual growth rate of approximately 11%. In the first three months of 2026, revenue grew 19.1% year-on-year to RMB 422 million. Gross margin improved from 49.6% to 53.7%, further climbing to 54.3% in early 2026—a cumulative gain of 4.7 percentage points during the period. Although early losses occurred due to acquisition integration costs, those losses narrowed year by year, and the company officially achieved profitability in 2025. Adjusted net profit reached RMB 129 million in 2025, while adjusted profit for the first three months of 2026 hit RMB 35 million, far exceeding the RMB 15.1 million recorded in the same period last year—an increase of over 130%. Adjusted EBITDA also grew to RMB 290 million, posting a 38.9% compound annual growth rate between 2023 and 2025.
Notably, adjusted profit and adjusted EBITDA exclude non-cash or non-operating items such as share-based compensation, intangible asset amortization, and certain one-off items, providing a clearer view of core business profitability. Furthermore, operating cash flow reached RMB 204 million in 2025, a significant improvement that confirms the company's ability to self-fund its growth cycle. For Hong Kong investors, whether Medicalc's IPO story holds enough appeal depends on the details that follow.
Global production and sales network taking shape with improving profitability metrics
Medicalc made its overseas moves early. The company originated in drug infusion products, and its infusion pumps have long earned a solid reputation in European markets: performance comparable to leading international brands and the only Chinese brand to receive a four-star rating in product evaluations by the US ECRI Institute. In recent years, the company deepened its overseas presence through strategic acquisitions. In 2022, it acquired UK-based Penlon, adding anesthesia and respiratory solutions to its life support portfolio. That same year, the acquisition of Vedekang Medical filled gaps in minimally invasive intervention products while opening doors across Asia, Europe, and the Americas. In 2025, it acquired European distributor Vedefar, bringing mature European market channels directly under its control.
These steps have expanded Medicalc's overseas footprint: overseas revenue accounted for 48.3% of total in 2025, covering over 140 countries and regions, with a global distributor network of more than 3,700 partners spanning Asia-Pacific, Europe, the Middle East, Africa, and the Americas. The company also established international training centers in the Netherlands, the UK, Colombia, and India, offering customized professional training for local customers and distributors—a localized "product plus service" model that builds brand influence and sustains overseas revenue growth.
At the same time, its domestic foundation remains solid: products have reached over 6,000 hospitals, with approximately 90% being top-tier Grade III-A institutions. By the end of 2025, the company had secured over 300 NMPA medical device registrations, more than 40 FDA clearances, and over 300 CE-certified products—compliance credentials that form an invisible competitive moat. Public data shows overseas revenue approaching half of total sales in 2025, driving the turnaround to profitability and margin expansion. Adjusted net profit reached RMB 129 million in 2025, adjusted EBITDA grew to RMB 290 million with a 38.9% CAGR from 2023 to 2025, and profitability indicators have improved markedly.
Innovation across multiple clinical scenarios builds advanced medical devices
Behind the impressive overseas performance lies Medicalc's long-standing commitment to independent innovation. The company is one of the few domestic players simultaneously covering three major tracks: life support, minimally invasive intervention, and in-vitro diagnostics. By the end of 2025, its product portfolio included over 60 life support products, 110 minimally invasive intervention products, and 150 IVD products—a scale and scope rarely seen among domestic device manufacturers. This means that from ICUs, operating rooms, and emergency departments to gastroenterology and respiratory units, most departments in a hospital can utilize Medicalc's offerings.
Each of the three segments plays a distinct role. The life support segment serves as the company's core foundation, maintaining steady revenue of RMB 500-600 million between 2023 and 2025. The minimally invasive intervention segment acts as a high-margin growth engine, with revenue leaping from RMB 587 million to RMB 812 million over three years, while gross margin expanded from 55.3% in 2023 to 61.8% in the first three months of 2026—now accounting for roughly half of total revenue.
Medicalc has invested heavily in innovation, operating an innovation center with 11 specialized divisions covering PCB design, algorithm research, whole-system testing, clinical trial management, and regulatory compliance. An "industry-academia-research-medicine" network ensures technological innovation stays aligned with real clinical needs. In 2025, R&D expenses reached RMB 274 million with a team of over 500 researchers holding more than 1,200 patents and patent applications.
The company's products are designed to address specific clinical pain points. The MP-80 multi-channel infusion workstation features a modular design that allows stacking of over a dozen infusion and syringe pumps without tools, meeting the critical needs of complex multi-channel infusion in ICUs. When connected to the iCMS central monitoring system, it enables hospital-wide centralized infusion management. Another product, the MS-100 remote-controlled infusion system, allows monitoring of infusion status from remote locations in ICUs, DSA operating rooms, hybrid operating rooms, and negative-pressure isolation wards, minimizing cross-infection and radiation exposure risks for healthcare workers.
With such a broad product portfolio and clinically relevant designs, it's easy to understand why Medicalc has already established leading positions in infusion workstations, enteral nutrition pumps, digestive system minimally invasive intervention consumables, and fully automated thromboelastography.
Investment outlook
The combination of favorable policy tailwinds and a clear earnings inflection point makes Medicalc's IPO an attractive investment opportunity. On the product side, full coverage across three major tracks with minimally invasive intervention leading growth, plus multiple world-first products addressing genuine clinical needs. On the market side, years of overseas expansion paired with deep penetration into top-tier hospitals domestically have formed the foundation of a global footprint. On the financial side, the company has turned profitable, improved cash flow, expanded margins, and now holds real cash on its books—fundamental certainty is well established.
The medical device sector is characterized by high barriers and strong customer stickiness. Once a positive cycle takes hold, growth often accelerates beyond expectations. What new stories Medicalc will tell next is certainly worth watching.